Strengths

Negative ROIC indicates capital deployment is still destroying value, leaving FEMY structurally behind profitable medtech peers that compound returns above cost of capital.

A current ratio above 2.0 provides some near-term liquidity cushion, but peers with stronger cash generation typically rely less on balance-sheet support to fund operations.

Net debt to EBITDA is negative, implying net cash rather than leverage, which is better than indebted peers but remains secondary to the company’s weak operating economics.

Weaknesses

ROIC below zero is the dominant weakness because it signals the business has not yet built a durable earnings engine, unlike stronger peers with positive capital efficiency.

The cash conversion cycle above 1,300 days reflects extreme working-capital inefficiency, materially worse than peers and consistent with a structurally fragile operating model.

A quick ratio below 1.0 suggests limited immediate liquidity after inventory and receivables, leaving FEMY more dependent on financing than better-capitalized competitors.

Debt to equity above 1.0 is elevated for an unprofitable small-cap medtech issuer, making the balance sheet less resilient than peers with cleaner capital structures.

Opportunities

If commercialization improves, FEMY has more operating leverage than mature peers because a small revenue base can translate incremental sales into faster margin recovery.

The net cash position gives management some flexibility to fund development and commercialization longer than leveraged peers, reducing near-term refinancing pressure.

Any improvement in working-capital discipline would have outsized impact because the current cash conversion cycle is so poor relative to peers and suppresses liquidity.

Threats

Persistent negative ROIC threatens long-term competitiveness because peers with positive returns can reinvest internally while FEMY may need repeated external capital.

The very long cash conversion cycle increases execution risk, since slower cash recovery can force dilution or financing before operating performance normalizes.

Weak quick liquidity raises vulnerability to demand or reimbursement delays, whereas stronger peers can absorb shocks without immediate balance-sheet strain.

Overall Score

FEMY’s structural positioning versus peers is weak because negative capital returns and severe working-capital inefficiency outweigh its modest liquidity and net-cash support.